Navigation Links
Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
Date:10/16/2009

Parallel Phase 2 studies could expedite development timeline

TSX Exchange Symbol: RVX

CALGARY, Oct. 16 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) provided an outline yesterday at the Company's Annual General Meeting for shareholders highlighting the Company's clinical plan path for Resverlogix's lead drug, RVX-208, for the treatment of cardiovascular disease.

Resverlogix outlined that the next two clinical studies will be performed in parallel. Start up activities for both studies have already commenced in conjunction with the Cleveland Clinic and the IVUS Steering Committee. The studies, following normal FDA submission guidelines, will include a Phase 2 Pilot Intravascular Ultrasound (IVUS) trial to examine early lipid effects, and atheroma plaque characterization of the coronary vessel wall in 60 acute coronary syndrome patients. In parallel to this, a Phase 2 Dose-Ranging trial will be conducted in 280 stable cardiovascular patients on standard of care therapy, including statins, examining lipid changes. Both of these clinical trials will dose patients with coronary disease who are on standard treatment for 13 weeks. The start-up activities for these trials have commenced with screening, randomization and first dosing expected in Q1 2010. Updates on future clinical trials will be announced as they progress.

"We have made a significant advancement in our clinical trial plans due to the successful results in our most recent Phase 1b/2a clinical trial," said Donald J. McCaffrey, President and CEO of Resverlogix. "We have now been able to initiate Phase 2 Pilot IVUS study activities. For the first time we will now be able to assess RVX-208 effects on actual atherosclerosis plaque within the arterial wall of the heart vessels. We are performing this study in the acute coronary syndrome population which is one of the prioritized patients groups. This is a significant miles
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 Pfenex ... engaged in the development of biosimilar therapeutics including ... today that its first quarter 2015 financial results ... before the open of market. At 8:30 am Eastern ... to discuss the financial results and provide a ...
(Date:5/1/2015)... 2015 Investor-Edge has initiated ... (NASDAQ: GENE ), Agilent Technologies Inc. (NYSE: ... TMO ), Sequenom Inc. (NASDAQ: SQNM ... Free research report on Genetic Technologies can be ... 30, 2015, the NASDAQ Composite ended at 4,941.42, ...
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, 2015 /PRNewswire/ ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer ... the company,s business at the Deutsche Bank 40 th ... . The presentation will take place on Wednesday, ... be accessed via a live webcast on the United Therapeutics ...
(Date:4/30/2015)... DIEGO , April 30, 2015   Tamir ... announced today an update on its Ebola antiviral therapy ... Tamir,s leading candidates, TMR004, is currently being evaluated and ... of the battle against Ebola. During the first quarter ... And Leadership Meeting To Accelerate The Evaluation of Potential ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4
... Overview , ... the separation and purification of a number of biological molecules. For ... A, or a protein may be purified on the basis of ... purifications take place in a chromatographic column with a relatively large ...
... Purpose , Agricultural ... effectively and efficiently using LC/MS/MS. These agricultural compounds are extracted from ... Overview , ... great importance on the identification and quantitation of insecticides and herbicides ...
... Abstract , ... techniques that produce highpurity total RNA from biological sources such as ... or other manual handling, and produce a highly pure product, free ... These new techniques respond to the ...
Cached Biology Technology:Use of ZipTip Pipette Tips for Microscale Affinity Mass Spectrometry 2Use of ZipTip Pipette Tips for Microscale Affinity Mass Spectrometry 3Identification of Insecticides and Herbicides by LC/MS/MS Using the API 2000 LC/MS/MS System 2Total RNA Purification from Cultured Cells Using the ABI PRISM 6700 Automated Nucleic Acid Workstation and Total RNA Lysis Reagents 2Total RNA Purification from Cultured Cells Using the ABI PRISM 6700 Automated Nucleic Acid Workstation and Total RNA Lysis Reagents 3Total RNA Purification from Cultured Cells Using the ABI PRISM 6700 Automated Nucleic Acid Workstation and Total RNA Lysis Reagents 4Total RNA Purification from Cultured Cells Using the ABI PRISM 6700 Automated Nucleic Acid Workstation and Total RNA Lysis Reagents 5Total RNA Purification from Cultured Cells Using the ABI PRISM 6700 Automated Nucleic Acid Workstation and Total RNA Lysis Reagents 6
(Date:4/2/2015)... BETHESDA, Md. , April 2, 2015 ... Salt Lake City , the American ... election of five new directors to its Board.  Members ... for the ACMG and for forming and advancing its ... the medical genetics profession. "It,s an eventful ...
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
(Date:3/26/2015)... -- The Granite Club, Canada,s ... today announced it has implemented a state-of-the-art access and ... members and staff, while restricting access to authorized users ... FST,s IMID Access system because it has the perfect ... staff, in addition to unparalleled security," said James ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... that increase the risk of developing endometriosis, a common ... of this often very painful condition, which has a ... Details of the research, carried out at ... Nuffield Department of Obstetrics & Gynaecology, University of Oxford; ...
... Men with type 1 diabetes may be able ... tissue, say Georgetown University Medical Center (GUMC) researchers who ... Cell Biology 50th annual meeting in Philadelphia. Their laboratory ... human spermatogonial stem cells (SSCs) extracted from testicular tissue ...
... treatment of breast cancer just because a woman is pregnant, ... Breast Group. This suggestion is based on study results ... Loibl presented this data at the 33rd Annual CTRC-AACR San ... the time we started the study in 2003, there was ...
Cached Biology News:Genetic variants linked to increased risk of common gynecological disease 2'Grow your own transplant' may be possible for men with type 1 diabetes 2Unique needs and outcomes of pregnant women with breast cancer identified 2
... product contains 5 ml Dynabeads® ... the monoclonal BerEP4 against the ... cell adhesion molecule). Also available ... 2 x 10e7 MNC in ...
albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
... Processing mini Tray (3 per pack), ... staining and blot processing.Automated staining of ... proteins and nucleic acid analysis.Prepares blots ... chromogenic detection.Programmable control of protocol, solution, ...
Biology Products: